Oncolytics Biotech (TSE:ONC) Shares Cross Below 200-Day Moving Average – What’s Next?

Shares of Oncolytics Biotech Inc. (TSE:ONC) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares trading hands.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. The firm has a market capitalization of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The business’s 50-day moving average price is C$14.90 and its 200-day moving average price is C$14.90.

Insider Activity at Oncolytics Biotech

In other Oncolytics Biotech news, insider Jared Ryan Kelly acquired 29,500 shares of the company’s stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the purchase, the insider directly owned 109,000 shares in the company, valued at approximately C$126,440. This trade represents a 37.11% increase in their position. Also, Director Patricia Andrews acquired 35,400 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average price of C$1.18 per share, with a total value of C$41,772.00. Following the completion of the transaction, the director directly owned 78,128 shares in the company, valued at approximately C$92,191.04. The trade was a 82.85% increase in their ownership of the stock. Insiders have acquired a total of 289,232 shares of company stock valued at $335,760 in the last quarter. 3.82% of the stock is owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.